Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Cancer Immunol Immunother. 2020 Aug;69(8):1565-1576. doi: 10.1007/s00262-020-02563-2. Epub 2020 Apr 18.
Tumor microenvironment is important in the progression of clear cell renal cell carcinoma (ccRCC), and its prognostic value is still unclear. Recent reports demonstrated tumor-infiltrating CD39CD8 T cells are abundant, but their function remains obscure. We aim to assess clinical value of CD39CD8 T cells and seek a potential therapeutic target in ccRCC.
We immunohistochemically evaluated clinical value of CD39CD8 T cells in a retrospective Zhongshan Hospital cohort of 243 ccRCC patients. Fresh tumor samples (n = 48), non-tumor tissues and peripheral blood for flow cytometry analyses were collected to analyze immune cell functions from Zhongshan Hospital. The survival benefit of tyrosine kinase inhibitors (TKIs) in this subpopulation was evaluated. Kaplan-Meier analysis and COX regression model were applied for survival analyses. Bioinformatics analysis performed in TCGA KIRC cohort and the scRNA-seq cohort.
We found that accumulation of CD39CD8 T cells indicated poor prognosis (p < 0.0001) and indicated therapeutic benefit of TKIs therapy (p = 0.015). CD39CD8 T cells showed decreased TNF-α and IFN-γ with elevated PD-1 and TIM-3 expression. Further analysis of tumor-infiltrating immune cell landscape in the ccRCC revealed the positive correlation between CD39CD8 T cells and Tregs (p = 0.037) and M2-polarized macrophages (p < 0.0001). Finally, inhibition of CD39 partially restores the anti-tumor function of CD8 T cells.
High CD39CD8 T cells indicated poor prognosis in ccRCC, due to impaired anti-tumor function of CD39CD8 T cells and indicated therapeutic benefit of TKIs therapy.
肿瘤微环境在透明细胞肾细胞癌(ccRCC)的进展中很重要,但其预后价值尚不清楚。最近的报告表明,肿瘤浸润性 CD39CD8 T 细胞丰富,但它们的功能仍不清楚。我们旨在评估 CD39CD8 T 细胞的临床价值,并寻找 ccRCC 的潜在治疗靶点。
我们采用免疫组织化学方法评估了 243 例 ccRCC 患者的中山医院回顾性队列中 CD39CD8 T 细胞的临床价值。收集新鲜肿瘤样本(n=48)、非肿瘤组织和外周血进行流式细胞术分析,以分析来自中山医院的免疫细胞功能。评估该亚群酪氨酸激酶抑制剂(TKI)治疗的生存获益。Kaplan-Meier 分析和 COX 回归模型用于生存分析。TCGA KIRC 队列和 scRNA-seq 队列进行生物信息学分析。
我们发现 CD39CD8 T 细胞的积累预示着预后不良(p<0.0001),并预示着 TKI 治疗的获益(p=0.015)。CD39CD8 T 细胞表现出 TNF-α 和 IFN-γ 的减少,同时 PD-1 和 TIM-3 的表达增加。对 ccRCC 肿瘤浸润免疫细胞景观的进一步分析表明,CD39CD8 T 细胞与 Tregs(p=0.037)和 M2 极化巨噬细胞(p<0.0001)之间呈正相关。最后,抑制 CD39 部分恢复了 CD8 T 细胞的抗肿瘤功能。
在 ccRCC 中,高 CD39CD8 T 细胞预示着预后不良,这是由于 CD39CD8 T 细胞的抗肿瘤功能受损以及 TKI 治疗的获益。